ENSC - Latest News
Ensysce Biosciences, Inc. (ENSC), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $2.8M. Beta to the broader market is 0.88.
The article list below shows the most recent ENSC headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ENSC Headlines
Ensysce Biosciences Reports First Quarter 2026 Financial Results
accessnewswire.com - May 15, 2026
~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~ ~ Clinical Peer-Reviewed Data Published for First Overdose Protected Opioid PF614-MPAR®; Patent Est
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
accessnewswire.com - May 12, 2026
~ Patent Extends Jurisdiction and Protection Through 2042 ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
accessnewswire.com - May 8, 2026
~ Chemical Control, Clinical Confidence: Rethinking Opioids ~ SAN DIEGO, CA / ACCESS Newswire / May 8, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)
Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
accessnewswire.com - Apr 16, 2026
~ Advances First-in-Class Opioid with Oral Overdose-Protection ~ SAN DIEGO, CA / ACCESS Newswire / April 16, 2026 / Ensysce Biosciences, Inc. (NASDAQ
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
accessnewswire.com - Apr 7, 2026
~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-resistant analgesics~ SAN DIEGO, CA / ACCESS Newswi
How News Affects ENSC Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ENSC's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ENSC news questions
- What is the latest ENSC news headline?
- The most recent ENSC headline (May 15, 2026) is "Ensysce Biosciences Reports First Quarter 2026 Financial Results". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ENSC news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ENSC news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ENSC options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.